0      0


AM21-56: COVID-19 Convalescent Plasma: Impact on Donation Safety and Eligibility


Oct 19, 2021 9:00pm ‐ Oct 19, 2021 10:00pm



Credits: None available.

Description


COVID-19 convalescent plasma (CCP) from individuals recently recovered from SARS-CoV-2 infection is an important therapeutic option for individuals at risk for severe complications from COVID-19. Ensuring donor safety is of paramount importance for collection of CCP. Common donor adverse events (DAEs) generally involve complications such as vasovagal reactions, local arm pain or hematomas, as well as reactions related to apheresis collections. Other unique aspects related to donor health in individuals recovered from COVID-19 must also be considered, including donors who have received COVID-19 Convalescent Plasma (CCP) or monoclonal antibody therapy, as well as SARS-CoV-2 vaccination post-recovery. The AABB Donor Hemovigilance Working Group will share the results from their multi-institutional study analyzing key safety metrics related to the collection of CCP. Join this session to learn about new insights on donor hemovigilance gleaned from recent efforts collecting CCP.

Speaker(s):

  • Dr. Jed B. Gorlin, MD, MBA, Medical Director and Vice President, Quality and Regulatory Affairs, Co-Director, Transfusion Medicine, Associate Clinical Professor, Laboratory Medicine and Pediatrics, Innovative Blood Resources
  • Dr. Mary Townsend, MD, Medical Director, Vitalant

Moderator(s):

Credits

Credits: None available.

You must be logged in and own this session in order to post comments.